FDA

AMA Moves to Ban Direct-To-Consumer Pharmaceutical Ads

According to the AMA, direct-to-consumer advertising of pharmaceuticals and medical devices drives up health care costs and should be banned. [More…]

Read More
By R Kennedy | Advertising . Antidepressant medication . Antipsychotic medication . Bipolar Depression . Bipolar Disorder . Depression . Direct-to-Consumer . Drug marketing . FDA . Health Industry . Mental health . News . Pharmaceutical Industry
DETAIL

Development and Regulation of Abuse-Deterrent Opioid Medications – FDA Public Meeting

The FDA is hosting a public meeting on October 30 and 31, 2014 to discuss the development, assessment, and regulation of abuse-deterrent formulations of opioid medications. The meeting will focus on scientific and technical issues related to the development and in vitro assessment of these products, as well as FDA’s approach towards assessing the benefits […]

Read More
By R Kennedy | Drugs . FDA . Opioids . Substance abuse
DETAIL